Celator Pharma (CPXX) 2.60 $CPXX
Celator(R) Pharmaceuticals Announces Business Update and First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 3:08PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported business highlights and financial results for the first quarter ended March 31, 2014.
Celator(R) Pharmaceuticals Secures Loan Agreement With Hercules Technology Growth Capital
GlobeNewswire - Mon May 12, 7:30AM CDT
Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC), a specialty finance company that provides customized debt financing to companies in life sciences and technology-related markets. Hercules will provide Celator with access to a term loan of up to $15 million.
Celator(R) Pharmaceuticals to Report First Quarter 2014 Financial Results on May 12, 2014
GlobeNewswire - Mon May 05, 8:42AM CDT
Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will host a conference call and live audio webcast on Monday, May 12, 2014 at 4:30 p.m. ET to report first quarter 2014 financial results.
Celator(R) Pharmaceuticals Announces Start of Clinical Study of CPX-351 in Relapsed/Refractory Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients
GlobeNewswire - Wed Mar 26, 3:01PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that patients have been enrolled in an investigator-initiated clinical study evaluating CPX-351 (cytarabine:daunorubicin) Liposome Injection as a treatment for patients with higher risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), who are refractory to or in relapse after hypomethylating agent (HMA) therapy.
Celator(R) Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 24, 3:01PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2013.
Celator(R) Pharmaceuticals to Report Fourth Quarter and Year-End 2013 Financial Results on March 24, 2014
GlobeNewswire - Tue Mar 18, 3:01PM CDT
Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will host a conference call and live audio webcast on Monday, March 24, 2014 at 4:30 p.m. ET to report fourth quarter and year-end 2013 financial results.
Celator(R) Pharmaceuticals Announces New Date and Time for Presentation at 16th Annual BIO CEO and Investor Conference
GlobeNewswire - Mon Feb 03, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, Chief Executive Officer, will now present an overview of the company at the 16 Annual BIO CEO and Investor Conference on Monday, February 10, 2014, at 9:00 a.m. EST. The conference is being held at the Waldorf Astoria in New York.
Celator(R) Pharmaceuticals to Present at Upcoming Healthcare Conferences
GlobeNewswire - Tue Jan 14, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, chief executive officer, will present an overview of the company at two upcoming healthcare conferences.
Celator(R) Pharmaceuticals Reaches 50% Enrollment for CPX-351 Phase 3 Study
GlobeNewswire - Thu Jan 09, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the Company's Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) has reached 50% of the study's planned enrollment of 300 patients.
Celator(R) Pharmaceuticals Approved for Approximately $1.5 Million From New Jersey's Technology Business Tax Certificate Transfer Program
GlobeNewswire - Tue Jan 07, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, announced today that the company has been approved for approximately $1.5 million, in non-dilutive financing, through New Jersey's Technology Business Tax Certificate Transfer Program.
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
GlobeNewswire - Thu Dec 19, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the appointment of Joseph M. Lobacki to its Board of Directors.
Celator(R) Pharmaceuticals Announces Positive Data and Safety Monitoring Board Recommendation for CPX-351 Phase 3 Study
GlobeNewswire - Thu Dec 12, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) should continue as planned without any modifications.
Celator(R) Pharmaceuticals to Present at Oppenheimer 24th Annual Healthcare Conference
GlobeNewswire - Fri Dec 06, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, chief executive officer, will present an overview of the Company at the upcoming Oppenheimer 24 Annual Healthcare Conference.
Celator(R) Pharmaceuticals Announces Business Update and Third Quarter 2013 Financial Results
GlobeNewswire - Tue Nov 12, 3:00PM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported third quarter 2013 financial results.
Celator(R) Pharmaceuticals Announces Appointment of Les Mintzmyer as Vice-President Manufacturing and Technical Operations
GlobeNewswire - Tue Nov 12, 6:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the appointment of industry veteran Les Mintzmyer as vice-president, manufacturing and technical operations. Mintzmyer will be responsible for optimizing the Company's production, supply chain logistics, customer service, quality, and regulatory compliance, while working closely with the Company's contract supply and manufacturing organizations in the planning and introduction of new products.
Celator(R) Pharmaceuticals Announces Business Update and First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 3:08PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported business highlights and financial results for the first quarter ended March 31, 2014.
Celator(R) Pharmaceuticals Secures Loan Agreement With Hercules Technology Growth Capital
GlobeNewswire - Mon May 12, 7:30AM CDT
Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC), a specialty finance company that provides customized debt financing to companies in life sciences and technology-related markets. Hercules will provide Celator with access to a term loan of up to $15 million.
Celator(R) Pharmaceuticals to Report First Quarter 2014 Financial Results on May 12, 2014
GlobeNewswire - Mon May 05, 8:42AM CDT
Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will host a conference call and live audio webcast on Monday, May 12, 2014 at 4:30 p.m. ET to report first quarter 2014 financial results.
Celator(R) Pharmaceuticals Announces Start of Clinical Study of CPX-351 in Relapsed/Refractory Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients
GlobeNewswire - Wed Mar 26, 3:01PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that patients have been enrolled in an investigator-initiated clinical study evaluating CPX-351 (cytarabine:daunorubicin) Liposome Injection as a treatment for patients with higher risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), who are refractory to or in relapse after hypomethylating agent (HMA) therapy.
Celator(R) Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 24, 3:01PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2013.
Celator(R) Pharmaceuticals to Report Fourth Quarter and Year-End 2013 Financial Results on March 24, 2014
GlobeNewswire - Tue Mar 18, 3:01PM CDT
Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will host a conference call and live audio webcast on Monday, March 24, 2014 at 4:30 p.m. ET to report fourth quarter and year-end 2013 financial results.
Celator(R) Pharmaceuticals Announces New Date and Time for Presentation at 16th Annual BIO CEO and Investor Conference
GlobeNewswire - Mon Feb 03, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, Chief Executive Officer, will now present an overview of the company at the 16 Annual BIO CEO and Investor Conference on Monday, February 10, 2014, at 9:00 a.m. EST. The conference is being held at the Waldorf Astoria in New York.
Celator(R) Pharmaceuticals to Present at Upcoming Healthcare Conferences
GlobeNewswire - Tue Jan 14, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, chief executive officer, will present an overview of the company at two upcoming healthcare conferences.
Celator(R) Pharmaceuticals Reaches 50% Enrollment for CPX-351 Phase 3 Study
GlobeNewswire - Thu Jan 09, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the Company's Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) has reached 50% of the study's planned enrollment of 300 patients.
Celator(R) Pharmaceuticals Approved for Approximately $1.5 Million From New Jersey's Technology Business Tax Certificate Transfer Program
GlobeNewswire - Tue Jan 07, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, announced today that the company has been approved for approximately $1.5 million, in non-dilutive financing, through New Jersey's Technology Business Tax Certificate Transfer Program.
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
GlobeNewswire - Thu Dec 19, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the appointment of Joseph M. Lobacki to its Board of Directors.
Celator(R) Pharmaceuticals Announces Positive Data and Safety Monitoring Board Recommendation for CPX-351 Phase 3 Study
GlobeNewswire - Thu Dec 12, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) should continue as planned without any modifications.
Celator(R) Pharmaceuticals to Present at Oppenheimer 24th Annual Healthcare Conference
GlobeNewswire - Fri Dec 06, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, chief executive officer, will present an overview of the Company at the upcoming Oppenheimer 24 Annual Healthcare Conference.
Celator(R) Pharmaceuticals Announces Business Update and Third Quarter 2013 Financial Results
GlobeNewswire - Tue Nov 12, 3:00PM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported third quarter 2013 financial results.
Celator(R) Pharmaceuticals Announces Appointment of Les Mintzmyer as Vice-President Manufacturing and Technical Operations
GlobeNewswire - Tue Nov 12, 6:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the appointment of industry veteran Les Mintzmyer as vice-president, manufacturing and technical operations. Mintzmyer will be responsible for optimizing the Company's production, supply chain logistics, customer service, quality, and regulatory compliance, while working closely with the Company's contract supply and manufacturing organizations in the planning and introduction of new products.
